July 11, 2022
The new article "Application of different approaches to generate virtual patient populations for the quantitative systems pharmacology model of erythropoiesis" by Galina Kolesova, Alexander Stepanov, Galina Lebedeva and Oleg Demin has been published in Journal of Pharmacokinetics and Pharmacodynamics.
Galina Kolesova comments on the article, "The traditional approach of QSP modeling includes fitting a model output to a series of mean data values. As a result, the parameters of the model represent fixed numbers enabling the description of mean data, thus we generated the so-called “reference patient”. However, the results of clinical trials include a description of variability in patients’ responses to a drug, which is typically expressed in terms of conventional statistical parameters such as standard deviations (SDs) from mean values. To allow a QSP model to reproduce the variability observed in response to a drug administration, a virtual patient (VP) population is usually generated and applied. In our study, we propose and compare four different approaches to generate virtual patient populations based on experimentally measured mean data and statistics, namely, (1) Monte Carlo Markov chain (MCMC), (2) model fitting to Monte Carlo samples, (3) population of clones, and (4) stochastically bounded selection. We applied these approaches to generate virtual patient populations in the QSP model of erythropoiesis. Our main task was to create a sample of virtual patients of the same size as that in clinical trials".
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Edinburgh, UK (INSYSBIO UK LIMITED), Moscow, Russia (INSYSBIO LLC) and Cyprus (INSYSBIO CY Ltd). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | March 2018 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
| |||
|
5
|
6
|
7
|
8
|
9
|
10
|
11
|
|
12
1.
12 Mar 2018 14:19
InSysBio to present at AAT-AD/PD Focus Meeting 2018
InSysBio today announced their participation at AAT-AD/PD Focus Meeting 2018, to be held in Torino, Italy, on March 15-18, 2018. The Meeting is focused on all the latest breakthroughs in treatment and research in Alzheimer’s, Parkinson’s and other neurological diseases. Alexander Stepanov will present “In silico implementation of tauopathy transgenic mouse model” in the framework of session “Symposium 25: Tau in translational studies (2)”.
|
13
|
14
|
15
1.
15 Mar 2018 15:43
InSysBio to present at the ASCPT 2018 Annual Meeting
InSysBio today announced their participation at the ASCPT 2018 Annual Meeting, to be held in Orlando, FL, on March 21-24.
|
16
|
17
|
18
|
|
19
|
20
|
21
|
22
|
23
|
24
|
25
|
|
26
|
27
|
28
|
29
|
30
|
31
| |
Thank you for your message! We will get back to you shortly.
